# Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

> **NCT04065165** · PHASE3 · WITHDRAWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Small Intestinal NET
- Carcinoid Heart Disease

## Interventions

- **DRUG:** Telotristat Ethyl
- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT04065165
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04
- **Primary completion:** 2023-07
- **Final completion:** 2027-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065165, "Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04065165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*